Prophylaxis followed by preemptive therapy versus preemptive therapy for prevention of human cytomegalovirus disease in pediatric patients undergoing liver transplantation

Transplantation

Volumn 86, Issue 1, 2008, Pages 163-166

  Gerna, Giuseppe ^a   Lilleri, Daniele ^a   Callegaro, Annapaola ^b   Goglio, Antonio ^b   Cortese, Serena ^b   Stroppa, Paola ^b   Torre, Giuliano ^b  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b OSPEDALI RIUNITI   (Italy)

Author keywords

Human cytomegalovirus; Pediatric liver transplantation; Preemptive therapy; Prophylaxis

Indexed keywords

GANCICLOVIR; STEROID; TACROLIMUS; ANTIVIRUS AGENT; CYTOMEGALOVIRUS MATRIX PROTEIN 65KDA; MATRIX PROTEIN; PHOSPHOPROTEIN; VIRUS ANTIGEN; VIRUS DNA;

ANTIVIRAL THERAPY; ARTICLE; BLOOD; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; GENE NUMBER; GRAFT REJECTION; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNE RESPONSE; INFANT; LIVER TRANSPLANTATION; PATIENT MONITORING; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; SEROLOGY; T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOMEGALOVIRUS; DRUG ADMINISTRATION; DRUG EFFECT; GENETICS; IMMUNOLOGY; PRESCHOOL CHILD; TREATMENT OUTCOME;

ANTIGENS, VIRAL; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; GANCICLOVIR; HUMANS; IMMUNITY, CELLULAR; INFANT; LIVER TRANSPLANTATION; PHOSPHOPROTEINS; T-LYMPHOCYTES; TREATMENT OUTCOME; VIRAL MATRIX PROTEINS;

EID: 49849106318     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31817889e4     Document Type: Article

References (31)

1. Einsele H, Ehninger G, Hebart H, et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995; 86: 2815.
2. Boeckh M, Gooley TA, Myerson D, et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: A randomized double-blind study. Blood 1996; 88: 4063.
3. GaneE,Saliba F,Valdecasas GJC, etal. Randomized trialof efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. Lancet 1997; 350: 1729.
4. Ljungman P, Aschan J, Lewensohn-Fuchs I, et al. Results of different strategies for reducing cytomegalovirus-associated mortality in alloge-neic stem cell transplant recipients. Transplantation 1998; 66: 1330.
5. Lowance D, Neumayer HH, Legendre CM, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999; 340: 1462.
6. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganci-clovir vs oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611.
7. Singh N. Late-onset cytomegalovirus disease as a significant complication in solid organ transplant recipients receiving antiviral prophylaxis: A call to heed the mounting evidence. Clin Infect Dis 2005; 40: 704.
8. Locatelli F, Percivalle E, Comoli P, et al. Human cytomegalovirus (HCMV) infectionin paediatric patients given allogeneic bone marrow transplantation: Role of early antiviral treatment for HCMV antigen-emia on patients' outcome. Br J Hematol 1994; 88: 64.
9. Gerna G, Lilleri D, Baldanti F, et al. Human cytomegalovirus immediate-early mRNAemia versus pp65 antigenemia for guiding preemptive therapy in children and young adults undergoing hematopoietic stem cell transplantation: A prospective, randomized, open-label trial. Blood 2003; 101: 5053.
10. Snydman DR. Counterpoint: Prevention of infection and cytomegalo-virus (CMV) disease in recipients of solid organ transplants: The case for prophylaxis. Clin Infect Dis 2005; 40: 709.
11. Hodson EM, Jones CA, Webster AC, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solidorgan transplants: A systematic review of randomized controlled trials. Lancet 2005; 365: 2105.
12. Strippoli GF, Hodson EM, Jones C, et al. Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients. Transplantation 2006; 81: 139.
13. Kalil AC, Levitsky J, Lyden E, et al. Meta-analysis: The efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005; 143: 870.
14. Small LN, Lau J, Snydman DR. Preventing post-organ transplant cyto-megalovirus disease with ganciclovir: A meta-analysis comparing prophylactic and preemptive therapies. Clin Infect Dis 2006; 43: 869.
15. Meylan PR-A, Pascual M. Preemptive versus prophylactic approaches in the management of cytomegalovirus disease in solid organ trans- plant recipients: What we know and what we do not know. Clin Infect Dis 2006; 43: 881.
16. Koury JA, Storch GA, Bohl DL, et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006; 6: 2134.
17. Seu P, Winston D, Holt CD, et al. Long-term ganciclovir prophylaxis for successful prevention of primary cytomegalovirus (CMV) disease in CMV-seronegative liver transplant recipients with CMV seropositive donors. Transplantation 1997; 64: 1614.
18. Kelly DA. Current issues in pediatric transplantation. Pediatr Transplant 2006; 10: 712.
19. Spivey JF, Singleton D, Sweet S, et al. Safety and efficacy of prolonged cytomegalovirus prophylaxis with intravenous ganciclovir in pediatric and young adult lung transplant recipients. Pediatr Transplant 2007; 11: 312.
20. Lilleri D, Gerna G, Furione M, et al. Use of a DNAemia cut-off for monitoring human cytomegalovirus infection reduces the number of preemptively treated children and young adults receiving hematopoietic stem-cell Transplantation compared with qualitative pp65 antigen-emia. Blood 2007; 110: 2757.
21. Gerna G, Baldanti F, Torsellini M, et al. Evaluation of cytomegalovirus DNAemia versus pp65-antigenemia cutoff for guiding preemptive therapy in transplant recipients: A randomized study. Antivir Ther 2007; 12: 63.
22. Ljungman P, Griffiths P, Paya C. Definitions of HCMV infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094.
23. King SM, Superina R, Andrews W, et al. Randomized comparison of ganciclovir plus intravenous immune globulin (IVIG) with IVIG alone for prevention of primary cytomegalovirus disease in children receiving liver transplants. Clin Infect Dis 1997; 25: 1173.
24. Gerna G, Lilleri D. Monitoring transplant patients for human cytomegalovirus: Diagnostic update. Herpes 2006; 13: 4.
25. Gerna G, Revello MG, Percivalle E, et al. Comparison of different immu-nostaining techniques and monoclonal antibodies to the lower matrix phosphoprotein (pp65) for optimal quantitation of human cytomegalovirus antigenemia. J Clin Microbiol 1992; 30:1232.
26. Gerna G, Percivalle E, Torsellini M, et al. Standardization of the human cytomegalovirus antigenemia assay by means of in vitro generated pp65-positive peripheral Blood polymorphonuclear leukocytes. J Clin Microbiol 1998; 36: 3585.
27. Gerna G, Vitulo P, Rovida F, et al. Impact of metapneumovirus and human cytomegalovirus versus other respiratory viruses on the lower respiratory tract infections of lung transplant recipients. J Med Virol 2006; 78: 408.
28. + T cells by a novel method using monocyte-derived HCMV-infected immature dendritic cells. Eur J Immunol 2005; 35: 1795.
29. Rubin RH. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation. JAMA 1989; 261: 3607.
30. Seehofer D, Meisel H, Rayes N, et al. Prospective evaluation of the clinical utility of different methods for the detection of human cytomegalovirus disease after liver transplantation. Am J Transplant 2004; 4: 1331.
31. Kusne S, Grossi P, Irish W, et al. Cytomegalovirus PP65 antigenemia monitoring as a guide for preemptive therapy: A cost effective strategy for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation 1999; 68: 1125.